Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2020

Open Access 01-12-2020 | Coronavirus | Research article

Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19

Authors: Mahir Fidahic, Danijela Nujic, Renata Runjic, Marta Civljak, Filipa Markotic, Zvjezdana Lovric Makaric, Livia Puljak

Published in: BMC Medical Research Methodology | Issue 1/2020

Login to get access

Abstract

Background

The research community reacted rapidly to the emergence of COVID-19. We aimed to assess characteristics of journal articles, preprint articles, and registered trial protocols about COVID-19 and its causal agent SARS-CoV-2.

Methods

We analyzed characteristics of journal articles with original data indexed by March 19, 2020, in World Health Organization (WHO) COVID-19 collection, articles published on preprint servers medRxiv and bioRxiv by April 3, 2010. Additionally, we assessed characteristics of clinical trials indexed in the WHO International Clinical Trials Registry Platform (WHO ICTRP) by April 7, 2020.

Results

Among the first 2118 articles on COVID-19 published in scholarly journals, 533 (25%) contained original data. The majority was published by authors from China (75%) and funded by Chinese sponsors (75%); a quarter was published in the Chinese language. Among 312 articles that self-reported study design, the most frequent were retrospective studies (N = 88; 28%) and case reports (N = 86; 28%), analyzing patients’ characteristics (38%). Median Journal Impact Factor of journals where articles were published was 5.099.
Among 1088 analyzed preprint articles, the majority came from authors affiliated in China (51%) and were funded by sources in China (46%). Less than half reported study design; the majority were modeling studies (62%), and analyzed transmission/risk/prevalence (43%).
Of the 927 analyzed registered trials, the majority were interventional (58%). Half were already recruiting participants. The location for the conduct of the trial in the majority was China (N = 522; 63%). The median number of planned participants was 140 (range: 1 to 15,000,000). Registered intervention trials used highly heterogeneous primary outcomes and tested highly heterogeneous interventions; the most frequently studied interventions were hydroxychloroquine (N = 39; 7.2%) and chloroquine (N = 16; 3%).

Conclusions

Early articles on COVID-19 were predominantly retrospective case reports and modeling studies. The diversity of outcomes used in intervention trial protocols indicates the urgent need for defining a core outcome set for COVID-19 research. Chinese scholars had a head start in reporting about the new disease, but publishing articles in Chinese may limit their global reach. Mapping publications with original data can help finding gaps that will help us respond better to the new public health emergency.
Literature
4.
go back to reference Civljak R, Markotic A, Kuzman I. The third coronavirus epidemic in the third millennium: what's next? Croat Med J. 2020;61(1):1–4.CrossRef Civljak R, Markotic A, Kuzman I. The third coronavirus epidemic in the third millennium: what's next? Croat Med J. 2020;61(1):1–4.CrossRef
7.
go back to reference Jackson JL, Kuriyama A, Anton A, Choi A, Fournier JP, Geier AK, Jacquerioz F, Kogan D, Scholcoff C, Sun R. The accuracy of Google translate for abstracting data from non-English-language trials for systematic reviews. Ann Intern Med. 2019;171(9):677–9.CrossRef Jackson JL, Kuriyama A, Anton A, Choi A, Fournier JP, Geier AK, Jacquerioz F, Kogan D, Scholcoff C, Sun R. The accuracy of Google translate for abstracting data from non-English-language trials for systematic reviews. Ann Intern Med. 2019;171(9):677–9.CrossRef
10.
go back to reference Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. Journal of the Chinese Medical Association : JCMA. 2020;83(3):217–20.CrossRef Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. Journal of the Chinese Medical Association : JCMA. 2020;83(3):217–20.CrossRef
12.
go back to reference Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):iii ix-xi, 1-193.CrossRef Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):iii ix-xi, 1-193.CrossRef
13.
go back to reference Eisen MB, Akhmanova A, Behrens TE, Weigel D. Publishing in the time of COVID-19. Elife. 2020;9. Eisen MB, Akhmanova A, Behrens TE, Weigel D. Publishing in the time of COVID-19. Elife. 2020;9.
14.
go back to reference Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med. 2017;376(4):383–91.CrossRef Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med. 2017;376(4):383–91.CrossRef
15.
go back to reference Jin X, Pang B, Zhang J, Liu Q, Yang Z, Feng J, Liu X, Zhang L, Wang B, Huang Y, et al. Core outcome set for clinical trials on coronavirus disease 2019 (COS-COVID). Engineering (Beijing). 2020. Jin X, Pang B, Zhang J, Liu Q, Yang Z, Feng J, Liu X, Zhang L, Wang B, Huang Y, et al. Core outcome set for clinical trials on coronavirus disease 2019 (COS-COVID). Engineering (Beijing). 2020.
18.
go back to reference Wolkewitz M, Puljak L. Methodological challenges of analysing COVID-19 data during the pandemic. BMC Med Res Methodol. 2020;20(1):81.CrossRef Wolkewitz M, Puljak L. Methodological challenges of analysing COVID-19 data during the pandemic. BMC Med Res Methodol. 2020;20(1):81.CrossRef
20.
go back to reference Borges do Nascimento IJ, O'Mathuna DP, von Groote TC, Abdulazeem HM, Weerasekara I, Marusic A, Puljak L, Tassoni Civile V, Zakarija-Grkovic I, Poklepovic Pericic T et al: coronavirus disease (covid-19) pandemic: an overview of systematic reviews. medRxiv 2020.04.16.20068213; doi: https://doi.org/https://doi.org/10.1101/2020.04.16.20068213. Borges do Nascimento IJ, O'Mathuna DP, von Groote TC, Abdulazeem HM, Weerasekara I, Marusic A, Puljak L, Tassoni Civile V, Zakarija-Grkovic I, Poklepovic Pericic T et al: coronavirus disease (covid-19) pandemic: an overview of systematic reviews. medRxiv 2020.04.16.20068213; doi: https://​doi.​org/​https://​doi.​org/​10.​1101/​2020.​04.​16.​20068213.
Metadata
Title
Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19
Authors
Mahir Fidahic
Danijela Nujic
Renata Runjic
Marta Civljak
Filipa Markotic
Zvjezdana Lovric Makaric
Livia Puljak
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2020
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-020-01047-2

Other articles of this Issue 1/2020

BMC Medical Research Methodology 1/2020 Go to the issue